Wasatch Advisors Inc. Has $9.59 Million Stake in Omnicell, Inc. (OMCL)
Wasatch Advisors Inc. raised its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 21.7% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 133,317 shares of the company’s stock after acquiring an additional 23,816 shares during the quarter. Wasatch Advisors Inc.’s holdings in Omnicell were worth $9,585,000 as of its most recent filing with the SEC.
Several other large investors have also added to or reduced their stakes in OMCL. SG Americas Securities LLC raised its stake in Omnicell by 1,281.5% during the 3rd quarter. SG Americas Securities LLC now owns 26,636 shares of the company’s stock valued at $1,915,000 after acquiring an additional 24,708 shares during the last quarter. Stone Ridge Asset Management LLC purchased a new stake in Omnicell during the 3rd quarter valued at approximately $202,000. First National Bank of Omaha raised its stake in Omnicell by 2.9% during the 3rd quarter. First National Bank of Omaha now owns 33,102 shares of the company’s stock valued at $2,380,000 after acquiring an additional 925 shares during the last quarter. WINTON GROUP Ltd purchased a new stake in Omnicell during the 3rd quarter valued at approximately $15,107,000. Finally, Wells Fargo & Company MN raised its stake in Omnicell by 1.7% during the 3rd quarter. Wells Fargo & Company MN now owns 197,630 shares of the company’s stock valued at $14,210,000 after acquiring an additional 3,353 shares during the last quarter. 98.80% of the stock is owned by institutional investors and hedge funds.
Several analysts have commented on the company. Wells Fargo & Co upped their price objective on Omnicell from $59.00 to $61.00 and gave the company a “market perform” rating in a research note on Monday, October 29th. Craig Hallum upped their price objective on Omnicell from $65.00 to $80.00 and gave the company a “buy” rating in a research note on Monday, September 17th. Piper Jaffray Companies upped their price objective on Omnicell from $44.00 to $55.00 and gave the company a “neutral” rating in a research note on Friday, July 27th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $63.00 price objective on shares of Omnicell in a research note on Thursday, July 26th. Finally, BidaskClub downgraded Omnicell from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 4th. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $70.88.
Shares of OMCL stock opened at $69.19 on Thursday. The company has a market cap of $2.79 billion, a PE ratio of 384.39, a price-to-earnings-growth ratio of 4.21 and a beta of 0.98. Omnicell, Inc. has a 12-month low of $39.75 and a 12-month high of $74.16. The company has a quick ratio of 1.32, a current ratio of 1.78 and a debt-to-equity ratio of 0.27.
ILLEGAL ACTIVITY NOTICE: “Wasatch Advisors Inc. Has $9.59 Million Stake in Omnicell, Inc. (OMCL)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/11/15/wasatch-advisors-inc-has-9-59-million-stake-in-omnicell-inc-omcl.html.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.
Further Reading: What is the float in trading stocks?
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.